Zobrazeno 1 - 10
of 795
pro vyhledávání: '"Daniel A. Scott"'
Autor:
Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
ABSTRACTUse of pneumococcal conjugate vaccines (PCVs) has led to substantial reductions in the global burden of pediatric pneumococcal disease. Expansion of serotype coverage has been achieved by increasing PCV valency, but this may carry the potenti
Externí odkaz:
https://doaj.org/article/eee4a903246c45198a86e37958cb0a5c
Autor:
Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Streptococcus pneumoniae causes a considerable disease burden among children in China. Many isolates exhibit antimicrobial resistance but are often serotypes covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Because the approved infant
Externí odkaz:
https://doaj.org/article/7ff57e54ee8d442ab81f92b884b68d48
Autor:
Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Da
Externí odkaz:
https://doaj.org/article/c1b7ed93b86145a38cb32c74e643741f
Autor:
Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2691-2699 (2021)
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional co
Externí odkaz:
https://doaj.org/article/e0a61e1e225742c5b2e9ce10b62e0c70
Autor:
David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2249-2256 (2021)
Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes
Externí odkaz:
https://doaj.org/article/0b3347e2452941a9b4e2d5703b0f8e80
Autor:
Erica Chilson, Daniel A. Scott, Beate Schmoele-Thoma, Wendy Watson, Mary M. Moran, Raul Isturiz
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 11, Pp 2758-2772 (2020)
Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We co
Externí odkaz:
https://doaj.org/article/e2526bd06d9d4a5e8b9126dbfa9a8b9e
Autor:
Beate Schmoele-Thoma, Martin van Cleeff, Richard N. Greenberg, Alejandra Gurtman, Thomas R. Jones, Vani Sundaraiyer, William C. Gruber, Daniel A. Scott
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 575-583 (2019)
Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study ass
Externí odkaz:
https://doaj.org/article/7bf4a0d04de040828e72727f6c837456
Autor:
Allison R. Thompson, Nicola P. Klein, H. Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 444-451 (2019)
Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with coadministration and previous pneumococcal polysaccharide vaccination. This study assessed safety
Externí odkaz:
https://doaj.org/article/538518ef02b44b0b88cb3f4861a8e7c6
Autor:
Christine Juergens, James Trammel, Yasuko Shoji, Scott Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 8, Pp 1948-1956 (2018)
Injection site reactions (ISRs; redness, swelling and pain) commonly occur within 1–2 days after vaccination. After administration of toxoid vaccines including diphtheria toxoid, a later onset of ISRs has also been observed. As the serotype capsula
Externí odkaz:
https://doaj.org/article/2d2e4e785345446ba9adade0dd1bf60c
Autor:
Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 9, Pp 2065-2071 (2017)
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the
Externí odkaz:
https://doaj.org/article/afc33cd2bb744b43a87b5250a19ac0cc